peoplePerson
You Lu
Ran the first clinical trial of CRISPR-edited T cells in humans, in patients with lung cancer.
You Lu leads thoracic oncology at West China Hospital and conducted the first-in-human trial of PD-1-edited T cells using CRISPR, published in 2020, alongside lung cancer radiotherapy and immunotherapy research.
Role
Professor of Thoracic Oncology, West China Hospital, Sichuan University
Institution
Specialisms
Lung cancerRadiation oncologyCRISPR-edited T cellsImmunotherapy
| Title | Journal | Year |
|---|---|---|
| Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer | Nature Medicine | 2020 |
Pages like this
not linked directly; found by shared links- PersonWeimin Li
Shares West China Hospital, Sichuan University, Non-small-cell lung cancer.
- IdeaPublic cell-therapy foundries at cancer centres for academics and start-ups
Shares TCR-T cell therapy, CAR-T cell therapy.
- IdeaMake bespoke mouse cancer models in weeks with in vivo gene editing
Shares CRISPR functional genomics, Non-small-cell lung cancer.
- PersonAntoni Ribas
Shares TCR-T cell therapy, PD-1.
- InstitutionHenan Cancer Hospital
- PersonPhilip D. Greenberg
Shares TCR-T cell therapy, CAR-T cell therapy.
- CompanyCaribou Biosciences
- InstitutionChinese PLA General Hospital